Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -3 of 3
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Master Protocol: DMSO to Enable Standard Phase II Chemotherapeutic Drugs to Pass the Blood-Brain Barrier in Treatment of Brain Tumors --- ADR, CTX
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
60 and under
UMCC-8013
Last Modified:
7/10/2006
 
First Published:
6/25/2005
2.
Phase I Randomized Study of Adjuvant Transdermal Vaccine Therapy Comprising Multi-Epitope Melanoma Peptides, Tetanus Toxoid Helper Peptide, and Sargramostim (GM-CSF) in Combination With Either Montanide ISA-51 or Dimethyl Sulfoxide With or Without Imiquimod in Patients With Resected Stage II-IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
12 and over
NCI
UVACC-MEL-45
UVACC-HIC-11490, UVACC-34204, NCT00118313
3.
Chemotherapy with Cyclophosphamide and Dimethylsulfoxide for Metastatic Epidermoid Carcinoma of the Lung
Phase
Type
Status
Age
Sponsor
Protocol IDs
No phase specified
Treatment
Closed
under 60
UMCC-7713
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute